How late after completion of adjuvant capecitabine and radiation would you consider adjuvant olaparib for a patient with gBRCA mutated TNBC?

Given that olaparib was given within 12 weeks of completion of standard adjuvant therapy on the trial, will you still offer it to patients outside that window now that the data has been released? Would 1 year later be acceptable?

Answer from: Medical Oncologist at Academic Institution

OlympiA enrolled patients up to 12 weeks post adjuvant chemotherapy. So technically, this patient is within the window, but just barely. For a lower risk patient (e.g. small T1-T2N0, pCR after neoadjuvant therapy), I would probably not consider it one year after completing therapy. However, for a hi...

Comments

Medical Oncologist at Loyola University Chicago Stritch School of Medicine
See also this Q&A from UCLA tumor board regard...

Please select the option that best describes you:

How late after completion of adjuvant capecitabine and radiation would you consider adjuvant olaparib for a patient with gBRCA mutated TNBC?

Related Questions